SecBot SecBot
PRESS-RELEASE ·Filed May 18, 2026

NRXP

NRx Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The EPS beat and regulatory catalysts (ketamine ANDA decision Q3 2026, NRX-101 IND acceptance) are positive, but the company remains pre-revenue from pharmaceutical sales and operating losses are widening. Monitor the Q3 2026 FDA ANDA decision and the Geneuro asset acquisition closing for the next major catalysts. The $7M ATM raise post-quarter provides runway but dilutes existing holders.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.12
T+0 close · May 18, 2026 · via day close
Latest settled
+7.87%
T+60 · $3.36
Vs SPY
+3.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $3.12entry
  2. T+1 · 6mo ago −2.73%α −2.08% · $3.03
  3. T+5 · 6mo ago +38.36%α +36.74% · $4.31
  4. T+20 · 5mo ago +27.45%α +25.87% · $3.97
  5. T+60 · 3mo ago +7.87%α +3.01% · $3.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1.4M from $5.5M a year ago. The company advanced multiple regulatory milestones including an anticipated FDA ANDA decision on preservative-free ketamine in Q3 2026, initiated commercial manufacturing, and generated first revenue from its HOPE Therapeutics clinic network. The beat is notable for a clinical-stage biotech but driven by non-recurring fair value accounting changes rather than operational improvement.

Key Financial Metrics

EPS
−$0.04
est −$0.13 · +69.2%
Rating
strong beat

Key Facts

  • EPS -$0.04 vs consensus -$0.13 (69.2% beat)
  • Net loss narrowed to $1.4M from $5.5M YoY, though operating loss widened to $4.7M from $3.8M
  • Cash and equivalents $6.7M as of March 31, 2026; raised ~$7M post-quarter via ATM
  • FDA ANDA decision on preservative-free ketamine expected Q3 2026 with favorable preliminary determinations
  • Initiated commercial manufacturing at 1 million dose/month scale; FDA reclassified facility to VAI status
  • First revenue generated from five HOPE Therapeutics clinics with VA, DoD, and private insurer funding
  • Pending acquisition of Geneuro SA assets (patents, antibodies, Phase 2 data) via Swiss court liquidation
  • FDA accepted IND for NRX-101 as adjunct to robotic TMS; non-dilutive federal funding anticipated

Financial Impact

EPS beat of 69.2% on a -$0.13 consensus; net loss improvement of $4.1M YoY; $6.7M cash plus $7M post-quarter ATM proceeds

epsnet incomecash positionoperating loss

Risk Factors

  • FDA ANDA decision on ketamine could be delayed or result in a Complete Response Letter
  • Operating losses are widening ($4.7M vs $3.8M) despite net loss improvement from non-recurring items
  • Dilution risk from ongoing ATM facility; $7M raised post-quarter adds to share count
  • Clinical-stage biotech with no approved products; revenue from clinics is early-stage and small
  • Pending Geneuro acquisition may not close or deliver expected value

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3296477

Track record

22 reports on NRXP

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026